New drug combo shows promise for rare blood cancer

NCT ID NCT04817007

Ongoing Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called BMS-986158, either alone or combined with standard treatments (ruxolitinib or fedratinib), in about 216 people with high-risk myelofibrosis, a type of blood cancer. The goal is to see if the drug is safe and can shrink an enlarged spleen, a common problem in this disease. The trial is currently active but not recruiting new participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BMS-986158 (a drug being tested) combined with either ruxolitinib or fedratinib (standard drugs for myelofibrosis)
What this could lead to: If this works, it could offer a new treatment option for people with high-risk myelofibrosis, potentially shrinking an enlarged spleen and improving symptoms.
What could go wrong: This is an early-phase trial (Phase 1b/2) with a small number of participants, so the drug may not prove effective or safe. Side effects could be serious, and the combination might not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS

Contacts and locations

Locations

Local Institution - 0001

Florence, 50134, Italy
Local Institution - 0002

Brescia, 25123, Italy
Local Institution - 0003

Bologna, 40138, Italy
Local Institution - 0006

Heidelberg, Victoria, 3084, Australia
Local Institution - 0007

East Melbourne, Victoria, 3002, Australia
Local Institution - 0008

Marseille, 13273, France
Local Institution - 0010

Villejuif, 94800, France
Local Institution - 0011

Paris, 75010, France
Local Institution - 0012

Verona, 37134, Italy
Local Institution - 0015

West Perth, Western Australia, 6005, Australia
Local Institution - 0016

Jerusalem, 9112001, Israel
Local Institution - 0017

Ramat Gan, 5262100, Israel
Local Institution - 0018

Petah Tikva, 4910021, Israel
Local Institution - 0019

Tel Aviv, 6423906, Israel
Local Institution - 0020

Badalona, Barcelona [Barcelona], 08916, Spain
Local Institution - 0021

Salamanca, 37007, Spain
Local Institution - 0026

Madrid, 28041, Spain
Local Institution - 0027

Nice, 06202, France
Local Institution - 0029

Santander, Cantabria, 39008, Spain
Local Institution - 0030

Brest, 29200, France
Local Institution - 0032

Wollongong, New South Wales, 2500, Australia
Local Institution - 0033

Ann Arbor, Michigan, 48109, United States
Local Institution - 0035

Halle, Saxony-Anhalt, 06120, Germany
Local Institution - 0036

Blacktown, New South Wales, 2148, Australia
Local Institution - 0038

Worcester, Massachusetts, 01655, United States
Local Institution - 0039

Essen, North Rhine-Westphalia, 45122, Germany
Local Institution - 0040

Chemnitz, Saxony, 09116, Germany
Local Institution - 0041

Nedlands, Western Australia, 6009, Australia
Local Institution - 0042

Pittsburgh, Pennsylvania, 15224, United States
Local Institution - 0043

New Orleans, Louisiana, 70112, United States
Local Institution - 0045

Hackensack, New Jersey, 07601, United States
Local Institution - 0047

Thessaloniki, Thessaloníki, 570 10, Greece
Local Institution - 0048

Seoul, Seoul-teukbyeolsi [Seoul], 05505, South Korea
Local Institution - 0049

Seongnam, Kyǒnggi-do, 13620, South Korea
Local Institution - 0050

Lübeck, Schleswig-Holstein, 23538, Germany
Local Institution - 0051

Cluj-Napoca, 400015, Romania
Local Institution - 0052

Bucuresti, Cluj, 022328, Romania
Local Institution - 0053

Seoul, Seoul-teukbyeolsi [Seoul], 06591, South Korea
Local Institution - 0054

Madrid, Madrid, Comunidad de, 28034, Spain
Local Institution - 0061

Chaïdári, Attikí, 12462, Greece
Local Institution - 0062

Gdansk, 80-952, Poland
Local Institution - 0068

Erding, Bavaria, 85435, Germany
Local Institution - 0069

Newport Beach, California, 92663, United States
Local Institution - 0076

Chapel Hill, North Carolina, 27514, United States
Local Institution - 0077

Słupsk, Pomeranian Voivodeship, 76-200, Poland
Local Institution - 0083

Bucharest, 050098, Romania
Local Institution - 0086

Beersheba, Southern District, 8410101, Israel
Local Institution - 0090

Lake Mary, Florida, 32746, United States
Local Institution - 0094

Valencia, 46026, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.